Connection

Stephen Kent to HIV-1

Back to Details
This is a "connection" page, showing publications Stephen Kent has written about HIV-1.
Stephen Kent
Connection Strength
2.019
HIV-1
  1. Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV. 2019 06; 6(6):e406-e410.
    View in: PubMed
    Score: 0.265
  2. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology. 2018 08 22; 15(1):58.
    View in: PubMed
    Score: 0.252
  3. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses. 2018 06 18; 10(6).
    View in: PubMed
    Score: 0.249
  4. Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization? Curr Opin HIV AIDS. 2018 03; 13(2):160-166.
    View in: PubMed
    Score: 0.244
  5. HIV Reactivation after Partial Protection by Neutralizing Antibodies. Trends Immunol. 2018 05; 39(5):359-366.
    View in: PubMed
    Score: 0.243
  6. Expanding role for type I Interferons in restricting HIV growth. Immunol Cell Biol. 2017 05; 95(5):417-418.
    View in: PubMed
    Score: 0.230
  7. Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. Front Immunol. 2019; 10:1025.
    View in: PubMed
    Score: 0.066
  8. The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. AIDS Res Hum Retroviruses. 2018 09; 34(9):727-738.
    View in: PubMed
    Score: 0.063
  9. Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. J Virol. 2018 06 01; 92(11).
    View in: PubMed
    Score: 0.062
  10. Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. Proteomics. 2018 06; 18(12):e1700253.
    View in: PubMed
    Score: 0.061
  11. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV. 2018 05; 5(5):e221-e230.
    View in: PubMed
    Score: 0.061
  12. Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):345-353.
    View in: PubMed
    Score: 0.058
  13. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. J Virol. 2017 05 01; 91(9).
    View in: PubMed
    Score: 0.057
  14. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Virology. 2008 May 10; 374(2):528-34.
    View in: PubMed
    Score: 0.030
  15. Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models. J Virol. 2019 06 01; 93(11).
    View in: PubMed
    Score: 0.017
  16. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. J Immunol Methods. 2018 06; 457:41-52.
    View in: PubMed
    Score: 0.015
  17. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? J Virol. 2017 12 15; 91(24).
    View in: PubMed
    Score: 0.015
  18. Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. Hum Vaccin Immunother. 2017 11 02; 13(11):2726-2737.
    View in: PubMed
    Score: 0.015
  19. Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses. Vaccine. 2016 Feb 24; 34(9):1172-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.